Vice General Manager

Dr. Yen-Ning Kuo is our Vice General Manager, bringing extensive expertise in chemical engineering, pharmaceutical development, and strategic leadership to our team.

 

Education

Dr. Kuo's educational journey is rooted in excellence：

  • Bachelor's degree in Chemical Engineering, Tunghai University
  • Ph.D. in Chemical Engineering, University of California, Irvine (2003) - Awarded a prestigious scholarship for his doctoral dissertation.

 

Work Experience

Dr. Kuo has made significant contributions throughout his career in the pharmaceutical industry：

  • Currently serving as the COO of the Pharmaceutical Business Center at UBI Pharma Inc..
  • His responsibilities encompass a wide spectrum, including product line planning, R&D management, marketing, sales, and distribution of our products.

Dr. Kuo's career with us began in 2005, starting with his work at UBIP's formulation R&D of peptide vaccine products and quality control methods.

  • He took on the pivotal role of developing our first sterile injectable product for the U.S. market.
  • During this development, Dr. Kuo played a vital role in enhancing our CMC (Chemistry, Manufacturing, and Controls) and quality systems to meet stringent U.S. and European standards.
  • In 2013, his leadership resulted in UBI Pharma Inc. successfully obtaining the first product license from the U.S. for our sterile injectable product.
  • Moreover, he cultivated a top-tier regulatory team experienced in U.S. licensure application for pharmaceuticals.

Notably, from the end of 2010 to 2011, Dr. Kuo expanded his horizons by joining Jiangsu Meide Biotech, a subsidiary of Vita Gnomics Inc. in China. In this role：

  • He took charge of new drug development, product licensing, and strategic alliances in the Chinese market.

Dr. Kuo's remarkable journey in chemical engineering and pharmaceuticals, coupled with his dynamic leadership, has significantly contributed to the growth and success of our organization. His dedication and expertise continue to drive our commitment to excellence and innovation in the pharmaceutical sector.